Latest market price
13.87
-0.16-1.14%
Earnings
Down 1.1% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 14.45 | EPS (ttm) | 0.96 | Insider Own | 0.08% | Shs Outstand | 184.36M | Perf Week | 2.06% |
| Market Cap | 2.56B | Forward P/E | 11.72 | EPS next Y | 1.18 | Insider Trans | 0.00% | Shs Float | 24.55M | Perf Month | 1.46% |
| Enterprise Value | 3.05B | PEG | 1.37 | EPS next Q | 0.37 | Short Float | 12.77% | Perf Quarter | -12.49% | ||
| Income | 177.00M | P/S | 1.49 | EPS this Y | 3.82% | Short Ratio | 12.30 | Perf Half Y | -17.39% | ||
| Sales | 1.71B | P/B | 2.35 | EPS next Y | 10.44% | ROA | 8.19% | Short Interest | 3.13M | Perf YTD | -15.84% |
| Book/sh | 5.91 | P/C | 38.74 | EPS next 5Y | 10.55% | ROE | 16.96% | 52W High | 19.57 -29.13% | Perf Year | -9.82% |
| Cash/sh | 0.36 | P/FCF | 16.50 | EPS past 3/5Y | 43.75% — | ROIC | 10.11% | 52W Low | 12.88 7.69% | Perf 3Y | — |
| Dividend Est. | 0.16 (1.15%) | EV/EBITDA | 8.14 | Sales past 3/5Y | 6.85% — | Gross Margin | 25.47% | Volatility | 3.63% 2.99% | Perf 5Y | — |
| Dividend TTM | 0.16 (1.15%) | EV/Sales | 1.78 | EPS Y/Y TTM | 6.67% | Oper. Margin | 15.36% | ATR (14) | 0.46 | Perf 10Y | — |
| Dividend Ex-Date | Oct 01, 2026 | Quick Ratio | 1.17 | Sales Y/Y TTM | 5.55% | Profit Margin | 10.35% | RSI (14) | 53.13 | Recom | 2.83 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.08 | EPS Q/Q | -17.86% | SMA20 | 2.92% | Beta | 1.56 | Target Price | 18.75 |
| Payout | 16.64% | Debt/Eq | 0.52 | Sales Q/Q | 9.79% | SMA50 | -1.10% | Rel Volume | 1.12 | Prev Close | 14.03 |
| Employees | 2,554 | LT Debt/Eq | 0.51 | Earnings | Nov 04 | SMA200 | -13.43% | Avg Volume | 242.04K | Price | 13.87 |
| IPO Date | Feb 07, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -18.83% 5.48% | Net Debt/EBITDA | 1.33 | Volume | 270,726 | Change | -1.14% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-29-26 | Reiterated | Stifel Nicolaus | $18 → $19 | |
| May-07-26 | Reiterated | HSBC | $19 | |
| Dec-15-25 | Reiterated | Jefferies | Buy | $20 |
| Jul-28-25 | Downgrade | Stifel | Buy → Hold | |
| Jul-24-25 | Downgrade | B of A Securities | Neutral → Underperform | |
| Apr-21-25 | Reiterated | Stifel Nicolaus | $16 → $15 | |
| Mar-12-25 | Initiated | HSBC | Buy | $19 |
| Mar-04-25 | Initiated | Bernstein | Market Perform | $17 |
| Mar-04-25 | Initiated | Goldman Sachs | Neutral | $19 |
Latest News· Times ET
Oct-29-26
Oct-29-2604:10PM
Oct-26-26
Oct-21-26
Oct-21-2604:10PM
Oct-05-26
10:14AM
Oct-02-26
Sep-22-26
Sep-18-26
Sep-18-2604:02AM
Sep-10-26
Sep-10-2605:05AM
Sep-08-26
Sep-08-2604:10PM
Aug-25-26
Aug-25-2603:50AM
Aug-13-26
Aug-13-2603:48AM
Jul-30-26
Jul-29-26
Jul-28-26
Company
Titan America S.A. specializes in the production of construction supplies. The firm is involved in the fabrication and distribution of various items, including cement, pre-mixed concrete, crushed stone, powdered mortar, concrete blocks, and other related concrete commodities. This company serves clients across the globe.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 1,712 | 1,664 | 1,634 | 1,592 | — | — | |
| Cost of Goods Sold Incl. D&A | 1,275 | 1,229 | 1,218 | 1,228 | — | — | |
| Gross Profit | 436 | 435 | 417 | 363 | — | — | |
| Selling, General and Administrative Excl. Other | 172 | 163 | 154 | 122 | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | |
| Other Operating Expense | 1 | 0 | 11 | 16 | — | — | |
| Operating Income | 263 | 271 | 251 | 226 | — | — | |
| Interest Expense | 18 | 23 | 25 | 21 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -5 | -4 | -3 | -2 | — | — | |
| Net Income Before Taxes | 238 | 245 | 224 | 202 | — | — | |
| Income Taxes | 62 | 59 | 58 | 47 | — | — | |
| Consolidated Net Income | 177 | 185 | 166 | 155 | — | — | |
| Net Income From Continuing Operations | 177 | 185 | 166 | 155 | — | — | |
| Net Income | 177 | 185 | 166 | 155 | — | — | |
| EPS (Recurring) | 0.96 | 1.01 | 0.90 | 0.84 | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.96 | 1.01 | 0.90 | 0.84 | — | — | |
| EPS (Diluted) | 0.96 | 1.01 | 0.90 | 0.84 | — | — | |
| EBITDA | 375 | 376 | 349 | 314 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | 14.45 | 16.32 | — | — | — | — | |
| Price To Sales Ratio | 1.49 | 1.81 | — | — | — | — | |
| Gross Margin | 25.47 | 26.14 | 25.52 | 22.80 | — | — | |
| Operating Margin | 15.36 | 16.29 | 15.36 | 14.20 | — | — | |
| Net Margin | 10.34 | 11.12 | 10.16 | 9.74 | — | — | |
| Shares Outstanding | 184 | 183 | 184 | 184 | — | — | |
| Market Capitalization | 2,552 | 3,016 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bachmann James W. | Director | Mar 31 '26 | Option Exercise | 0.00 | 5,849 | 0 | 5,849 | Apr 09 |
| Van der Smissen Willem Jozef Ludwig | Director | Mar 31 '26 | Option Exercise | 0.00 | 5,849 | 0 | 5,849 | Apr 09 |
| Antholis William John | Director | Mar 31 '26 | Option Exercise | 0.00 | 5,849 | 0 | 5,849 | Apr 09 |
| Santos Sandra Maria Soares | Director | Mar 31 '26 | Option Exercise | 0.00 | 5,849 | 0 | 5,849 | Apr 09 |
| Wilt Lawrence Hugh Jr. | Chief Financial Officer | Mar 19 '26 | Buy | 14.93 | 20,000 | 298,600 | 20,000 | Mar 23 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.